Merck Rises 11% YTD: Should Investors Buy, Sell or Hold the Stock?

Merck is up 11% year to date, helped by Keytruda growth, pipeline progress and M&A that improve the longer-term outlook. Near-term upside is constrained by patent risk, a slump in Gardasil sales and generic competition. The article presents a mixed fundamental picture rather than a clear catalyst-driven move.

Analysis

Merck is up 11% year to date, helped by Keytruda growth, pipeline progress and M&A that improve the longer-term outlook. Near-term upside is constrained by patent risk, a slump in Gardasil sales and generic competition. The article presents a mixed fundamental picture rather than a clear catalyst-driven move.